How PepGen’s Stock Performance Highlights Risks & Promise for Neuromuscular Therapy
Explore PepGen Inc.’s biotech ambitions and volatile Nasdaq stock, noting its negative P/E, 52‑week highs and lows, and future therapeutic potential.
2 minutes to read

